Insider Trading Activity Audentes Therapeutics, Inc. (NASDAQ:BOLD) – SVP Sold 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Mary Newman , SVP of Audentes Therapeutics, Inc. (NASDAQ:BOLD) reportedly Sold 10,000 shares of the company’s stock at an average price of 20 for a total transaction amount of $200,000.00 SEC Form

Insider Trading History For Audentes Therapeutics, Inc. (NASDAQ:BOLD)

  • On 7/25/2016 Versant Ventures Iv, Llc, Major Shareholder, bought 35,000 with an average share price of $15.00 per share and the total transaction amounting to $525,000.00.View SEC Filing
  • On 7/25/2016 Orbimed Advisors Llc, Director, bought 33,334 with an average share price of $15.00 per share and the total transaction amounting to $500,010.00.View SEC Filing
  • On 7/25/2016 James E Flynn, Insider, bought 400,000 with an average share price of $15.00 per share and the total transaction amounting to $6,000,000.00.View SEC Filing
  • On 4/24/2017 5Am Partners Iii, Llc, Insider, bought 172,413 with an average share price of $14.50 per share and the total transaction amounting to $2,499,988.50.View SEC Filing
  • On 6/26/2017 Louis G Lange, Director, sold 15,000 with an average share price of $19.78 per share and the total transaction amounting to $296,700.00.View SEC Filing
  • On 7/12/2017 Matthew R Patterson, CEO, sold 2,850 with an average share price of $20.00 per share and the total transaction amounting to $57,000.00.View SEC Filing
  • On 7/13/2017 Matthew R Patterson, CEO, sold 15,000 with an average share price of $20.00 per share and the total transaction amounting to $300,000.00.View SEC Filing

    • Analyst Ratings For Audentes Therapeutics, Inc. (NASDAQ:BOLD)
    These are 3 Buy Ratings .
    The current consensus rating for Audentes Therapeutics, Inc. (NASDAQ:BOLD) is Buy (Score: 3.00) with a consensus target price of $22.25 , a potential (4.26% upside)

    Analyst Ratings History For Audentes Therapeutics, Inc. (NASDAQ:BOLD)

    • On 8/15/2016 Cowen and Company Initiated Coverage of rating Outperform
    • On 11/12/2016 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $24.00
    • On 5/1/2017 Leerink Swann Initiated Coverage of rating Outperform with a price target of $22.00
    • On 5/15/2017 Wedbush Reiterated Rating Ourperform with a price target of $20.00
    • On 8/16/2017 Evercore ISI Initiated Coverage of rating Outperform to Outperform with a price target of $23.00

    Recent Trading Activity for Audentes Therapeutics, Inc. (NASDAQ:BOLD)
    Shares of Audentes Therapeutics, Inc. closed the previous trading session at 21.34 up +0.62 2.99% with 83,024 shares trading hands.